Signatera Lymphoma Patient Discussion Guide
Read More
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Signatera Cancer Care Patient Discussion Guide
Read More
-
Signatera Gynecologic Patient Discussion Guide
Read More
-
Signatera Lung Patient Discussion Guide
Read More
-
Signatera CRC Patient Discussion Guide
Read More
-
Signatera Bladder Patient Discussion Guide
Read More
-
Signatera Breast Patient Discussion Guide
Read More
-
Navigating Low-Level ctDNA Positive: Interpretation, Context and Actionability
Watch Video
-
Genetics in Practice with Dr. Eric Wallace
Watch Video
-
Navigating MIBC management: Integrating ctDNA into clinical practice
Watch Video
-
A clinical perspective from Dr. Siddharth Sheth
See how Signatera™ MRD testing flagged HNSCC recurrence before CT imaging, providing a lead-time advantage that can inform treatment.
Watch Video
-
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
Kataoka, K, et al. JAMA Oncology, 2026
Read More
-
Redefining HNSCC Management with Signatera™ MRD Testing: A Multidisciplinary Perspective
Watch Video
-
My patient is Signatera-positive. Now What?
Watch Video
-
Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer
Read More
-
MRD Insights for Radiation Oncology in NSCLC
Watch Video
-
Latitude One Pager
Read More
-
Anal One Pager
Read More
-
HCC One Pager
Read More
-
MDT+TOMR One Pager
Read More
-
Loading More...
